Profil
Thomas Gahm has been Vice President of Research and Development for TriPath Oncology, Inc. since June, 2000.
He was Vice President of Computer Science for TriPath Imaging, Inc. from November, 1996 to May, 2000.
Previously, Dr. Gahm was Vice President of Computer Science for RIAS and RBL.
He was a Scientific Advisor and Project Coordinator of the Image Analysis Division for Kontron Electronics from 1983 to 1993.
Dr. Gahm received a degree in Engineering from the University of Stuttgart (Institute of Physical Electronics) and a PhD from the Medical and Technical University of Hannover, Germany.
Aktive Positionen von Thomas Gahm
| Unternehmen | Position | Beginn |
|---|---|---|
TriPath Oncology, Inc.
TriPath Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes molecular diagnostics and pharmacogenomic tests for cancer | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Thomas Gahm
| Unternehmen | Position | Ende |
|---|---|---|
TriPath Imaging, Inc.
TriPath Imaging, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes molecular diagnostic products | Corporate Officer/Principal | 30.05.2000 |
Ausbildung von Thomas Gahm
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
TriPath Imaging, Inc.
TriPath Imaging, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes molecular diagnostic products | Health Technology |
Universität Stuttgart
Universität Stuttgart Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Hannover
University of Hannover Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TriPath Oncology, Inc.
TriPath Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes molecular diagnostics and pharmacogenomic tests for cancer | Commercial Services |
















